Mitoquinone Helps Combat the Neurological, Cognitive, and Molecular Consequences of Open Head Traumatic Brain Injury at Chronic Time Point
Traumatic brain injury (TBI) is a heterogeneous disease in its origin, neuropathology, and prognosis, with no FDA-approved treatments. The pathology of TBI is complicated and not sufficiently understood, which is the reason why more than 30 clinical trials in the past three decades turned out unsucc...
Main Authors: | Muhammad Ali Haidar, Zaynab Shakkour, Chloe Barsa, Maha Tabet, Sarin Mekhjian, Hala Darwish, Mona Goli, Deborah Shear, Jignesh D. Pandya, Yehia Mechref, Riyad El Khoury, Kevin Wang, Firas Kobeissy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/2/250 |
Similar Items
-
Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects
by: Firas Kobeissy, et al.
Published: (2023-11-01) -
Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone
by: Helene Ismail, et al.
Published: (2020-10-01) -
MS-based glycomics: An analytical tool to assess nervous system diseases
by: Wenjing Peng, et al.
Published: (2022-11-01) -
National Neurotrauma Registry Data in Low- and Middle-Income Countries – Current Status and Future Requirements; Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”
by: Fiona Lecky
Published: (2023-12-01) -
The Nanotheranostic Researcher’s Guide for Use of Animal Models of Traumatic Brain Injury
by: Brandon Z. McDonald, et al.
Published: (2021-12-01)